Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04849364
Title Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer (PERSEVERE)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Bryan Schneider, MD

triple-receptor negative breast cancer


Capecitabine + GDC-0077

Atezolizumab + Capecitabine

Capecitabine + Talazoparib


Atezolizumab + Capecitabine + Talazoparib

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.